US Stem Cell Inc
U.S. Stem Cell, Inc. engages in the research, development, and commercialization of stem cell and regenerative treatments in the United States and internationally. The company develops MyoCell, an autologous muscle stem cell therapy which is preparing for phase II/III clinical trials for the treatment of heart damage in heart failure patients; MyoCell SDF-1, an autologous cell therapy which compl… Read more
US Stem Cell Inc (USRM) - Total Assets
Latest total assets as of March 2023: $68.04K USD
Based on the latest financial reports, US Stem Cell Inc (USRM) holds total assets worth $68.04K USD as of March 2023.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
US Stem Cell Inc - Total Assets Trend (2002–2022)
This chart illustrates how US Stem Cell Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
US Stem Cell Inc - Asset Composition Analysis
Current Asset Composition (December 2022)
US Stem Cell Inc's total assets of $68.04K consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 7.5% |
| Accounts Receivable | $4.33K | 6.4% |
| Inventory | $980.00 | 1.4% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2002–2022)
This chart illustrates how US Stem Cell Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: US Stem Cell Inc's current assets represent 100.0% of total assets in 2022, an increase from 87.8% in 2002.
- Cash Position: Cash and equivalents constituted 7.5% of total assets in 2022, down from 87.8% in 2002.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2002.
- Asset Diversification: The largest asset category is accounts receivable at 6.4% of total assets.
US Stem Cell Inc Competitors by Total Assets
Key competitors of US Stem Cell Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
US Stem Cell Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - US Stem Cell Inc generates 1.21x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - US Stem Cell Inc is currently not profitable relative to its asset base.
US Stem Cell Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.00 | 0.01 | 0.29 |
| Quick Ratio | 0.00 | 0.01 | 0.27 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-14.01 Million | $ -12.60 Million | $ -4.76 Million |
US Stem Cell Inc - Advanced Valuation Insights
This section examines the relationship between US Stem Cell Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.83 |
| Asset Growth Rate (YoY) | 33.4% |
| Total Assets | $68.04K |
| Market Capitalization | $56.37K USD |
Valuation Analysis
Near Book Valuation: The market values US Stem Cell Inc's assets close to their book value ( 0.83x), suggesting investors view the company's assets at approximately fair value.
Rapid Asset Growth: US Stem Cell Inc's assets grew by 33.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for US Stem Cell Inc (2002–2022)
The table below shows the annual total assets of US Stem Cell Inc from 2002 to 2022.
| Year | Total Assets | Change |
|---|---|---|
| 2022-12-31 | $68.04K | +33.41% |
| 2021-12-31 | $51.00K | -42.15% |
| 2020-12-31 | $88.15K | -1.88% |
| 2019-12-31 | $89.84K | -95.06% |
| 2018-12-31 | $1.82 Million | +13.70% |
| 2017-12-31 | $1.60 Million | +273.70% |
| 2016-12-31 | $427.64K | +86.65% |
| 2015-12-31 | $229.11K | +11.88% |
| 2014-12-31 | $204.78K | +137.73% |
| 2013-12-31 | $86.14K | -46.93% |
| 2012-12-31 | $162.31K | -39.55% |
| 2011-12-31 | $268.49K | -13.05% |
| 2010-12-31 | $308.80K | -83.45% |
| 2009-12-31 | $1.87 Million | +0.60% |
| 2008-12-31 | $1.86 Million | -83.62% |
| 2007-12-31 | $11.32 Million | +74.01% |
| 2006-12-31 | $6.51 Million | +10.89% |
| 2005-12-31 | $5.87 Million | +705.09% |
| 2004-12-31 | $729.00K | -20.85% |
| 2003-12-31 | $921.00K | -63.74% |
| 2002-12-31 | $2.54 Million | -- |